Cartesian Therapeutics, Inc. 8-K

What Happened
Cartesian Therapeutics, Inc. (RNAC) filed a Form 8-K on January 9, 2026 under Item 7.01 (Regulation FD Disclosure) to distribute an updated corporate slide presentation and issued a press release highlighting recent progress and its 2026 outlook. The slide deck is attached as Exhibit 99.1 and the press release as Exhibit 99.2 to the report.

Key Details

• Filing date: January 9, 2026 (Form 8-K).
• Exhibits included: Exhibit 99.1 — corporate slide presentation (Jan 2026); Exhibit 99.2 — press release issued Jan 9, 2026; Exhibit 104 — interactive XBRL cover page data.
• Disclosure made under Item 7.01 (Regulation FD disclosure) — information provided to the investment community via presentations and a press release.
• The filing does not report earnings, executive changes, mergers/acquisitions, or other material financial events in this 8-K.

Why It Matters
This filing provides investors with the company’s latest corporate presentation and a press release summarizing recent developments and management’s outlook for 2026. Retail investors should review the attached exhibits for specifics on product, clinical, or business updates that could influence the company’s near-term strategy or investor expectations. The 8-K itself is a distribution of information (Regulation FD) rather than a report of new financial results or corporate actions.